登录

Funing Technology Announces Closing of $1.4M Funding by Strategic Investor Shengjitang

作者: Mailman 2019-12-25 20:12
圣济堂
http://www.gzcth.net/
企业数据由 动脉橙 提供支持
糖尿病药品研发商 | IPO | 运营中
中国-贵州
2018-05-29
中国长城资产
查看

On December 14, 2019, Shanghai-based Funing Information Technology Co., Ltd. ("Funing Technology") has got tens of millions of yuan (US$1.4 million) in strategic financing from Shengjitang, a listed pharmaceutical company, and built a strategic partnership with the latter. After the completion of this round financing, Funing Technology’s valuation will reach 200 million.


Funing Technology focuses on the application of information technology in the field of medicine, medical services and healthcare. It uses the Internet and big data technology to provide online services such as diagnosis, drug purchase, and health management. The company reduces the time of medical treatment, optimize the supply chain, and provide users with a complete solution for medical treatment and drug purchase.


Through the integration of the medical software, the ERP system, and the modern logistics visual system, Funing Technology has built up an Internet ecosystem of big health prescription and online pharmacy in the mode of B2B, B2C and O2O. Xia Guilang, chairman of Funing Technology, said that the company's business is based on its self-developed product supply chain system to achieve the goal of reducing intermediate processes, lowering drug prices and serving the public.


Shengjitang focuses on the manufacturing of chemical products and medical drugs. Besides, by raising funds to set up oncology hospitals and diabetes hospitals, the company further extends its business to medical services. It plans to build up a medical health service platform, integrating pharmaceutical with medical services, to enhance its capacity for sustainable profitability and management.


Shengjitang has ten production lines in compliance with GMP standards, covering several kinds of products such as granules, tablets, capsules, tinctures, infusion soft bags, small-volume injections, films, raw material drugs, blood glucose meters, healthcare products, etc.

注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】力美康完成2000万元pre-A轮融资,为连锁药店提供“人货场”全面赋能

连锁药房一年关店400多家,新零售成为救命稻草?

谷歌风投、OrbiMed等多家顶级投资机构,他们在海外投什么医疗企业

【首发】德品医疗完成近亿元B轮融资,打造医院-家庭-社区智慧护理闭环

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Oncology Pharma拟完成3840万美元新轮融资,用于抗癌生物药物KTH-222的开发

2019-12-25
下一篇

Origincell Medical Snares $11.4M in Series A Funding Round

2019-12-25